Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Carcinoma, Hepatocellular 9Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Recurrence 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphedema 1Locally Advanced Bladder Cancer 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 117Rituximab 115fludarabine phosphate 79Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 55Whole-Body Irradiation 52Filgrastim 49Tacrolimus 43Cyclosporine 43Radiotherapy 41Busulfan 41Antilymphocyte Serum 38Etoposide 36Melphalan 34Lenalidomide 31Methotrexate 25fludarabine 23Cord Blood Stem Cell Transplantation 22Bortezomib 20Flow Cytometry 19Cytarabine 19Methylprednisolone 18Bendamustine Hydrochloride 18obinutuzumab 17Prednisone 15Granulocyte Colony-Stimulating Factor 15Carmustine 15sargramostim 14orelabrutinib 14Therapeutics 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell, Marginal Zone × Pharmaceutical Preparations × Clear all
NCT00210353 2019-06-06

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Phase 3 Completed
454 enrolled 16 charts
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT00210392 2015-03-30

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Terminated
12 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT00210327 2009-07-22

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Completed
33 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡